Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric D Mortenson

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Oncoimmunology|March 8, 2014
Anti-HER2/Neu passive-aggressive immunotherapyEric D Mortenson, Yang-Xin Fu
Current Pathobiology Reports|February 20, 2013
Adaptive Immune Responses and HER2/neu Positive Breast CancerEric D Mortenson, Yang-Xin Fu
Cellular & Molecular Immunology|November 22, 2011
Targeting and utilizing primary tumors as live vaccines: changing strategiesXuanming Yang, Eric D Mortenson, Yang-Xin Fu
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2013
Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cellsEric D Mortenson, SaeGwang Park, Zhujun Jiang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 20, 2012
Cetuximab-mediated tumor regression depends on innate and adaptive immune responsesXuanming Yang, Xunmin Zhang, Eric D Mortenson, et al.
Science Translational Medicine|July 4, 2014
Recipient NK cell inactivation and intestinal barrier loss are required for MHC-matched graft-versus-host diseaseSam C Nalle, H Aimee Kwak, Karen L Edelblum, et al.
Cancer Cell|August 17, 2010
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunitySaeGwang Park, Zhujun Jiang, Eric D Mortenson, et al.
BMC Cancer|September 3, 2014
Intratumoral heterogeneity impacts the response to anti-neu antibody therapyHyunkeun Song, Tae Oh Kim, Sun Young Ma, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Oncoimmunology|March 8, 2014
Anti-HER2/Neu passive-aggressive immunotherapyEric D Mortenson, Yang-Xin Fu
Current Pathobiology Reports|February 20, 2013
Adaptive Immune Responses and HER2/neu Positive Breast CancerEric D Mortenson, Yang-Xin Fu
Cellular & Molecular Immunology|November 22, 2011
Targeting and utilizing primary tumors as live vaccines: changing strategiesXuanming Yang, Eric D Mortenson, Yang-Xin Fu
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2013
Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cellsEric D Mortenson, SaeGwang Park, Zhujun Jiang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 20, 2012
Cetuximab-mediated tumor regression depends on innate and adaptive immune responsesXuanming Yang, Xunmin Zhang, Eric D Mortenson, et al.
Science Translational Medicine|July 4, 2014
Recipient NK cell inactivation and intestinal barrier loss are required for MHC-matched graft-versus-host diseaseSam C Nalle, H Aimee Kwak, Karen L Edelblum, et al.
Cancer Cell|August 17, 2010
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunitySaeGwang Park, Zhujun Jiang, Eric D Mortenson, et al.
BMC Cancer|September 3, 2014
Intratumoral heterogeneity impacts the response to anti-neu antibody therapyHyunkeun Song, Tae Oh Kim, Sun Young Ma, et al.
Pageof 1